-
公开(公告)号:US20040063135A1
公开(公告)日:2004-04-01
申请号:US10676079
申请日:2003-10-02
Applicant: Insight Strategy & Marketing Ltd. , Hadasit Medical Research Services and Development Ltd.
Inventor: Iris Pecker , Israel Vlodavsky , Yael Friedmann , Tuvia Peretz
IPC: C12Q001/68 , C07H021/04
CPC classification number: C12Y302/01166 , A61L27/34 , A61M15/009 , C07K16/40 , C12N9/2402 , G01N33/573 , G01N2333/988 , G01N2400/40
Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.
-
公开(公告)号:US12188047B2
公开(公告)日:2025-01-07
申请号:US15771046
申请日:2016-10-26
Inventor: Benjamin Eithan Reubinoff , Orna Singer , Osnat Bohana-Kashtan , Ofer Wiser
IPC: C12N5/079 , C12N5/00 , C12N5/0735 , G01N33/53
Abstract: A method of generating retinal pigment epithelium cells is disclosed. Cell populations comprising same and uses thereof are also disclosed.
-
公开(公告)号:US20240368141A1
公开(公告)日:2024-11-07
申请号:US18768262
申请日:2024-07-10
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor: Or KAKHLON , Miguel Enrique WEIL , Leonardo Javier SOLMESKY
IPC: C07D409/12 , A61P25/28 , C07D487/08
Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
-
公开(公告)号:US20240123124A1
公开(公告)日:2024-04-18
申请号:US18535139
申请日:2023-12-11
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , AZRIELI COLLEGE OF ENGINEERING JERUSALEM
Inventor: Yoav MINTZ , Nikolai KUNICHER , Tali TAVOR RE'EM
IPC: A61L31/04 , A61F2/00 , A61K31/734 , A61K33/14
CPC classification number: A61L31/042 , A61F2/0063 , A61K31/734 , A61K33/14 , A61F2002/0072
Abstract: Disclosed herein are devices/kits and methods for reducing, treating, preventing or eliminating post-operative adhesions in an intervention/target site within a body of a subject. The method comprises the steps of: introducing an applicator, configured for applying an anti-adhesive composition, into an intervention/target site within a body of a subject; applying the anti-adhesive composition onto the intervention/target site; and extracting the applicator from the body of the subject, wherein the method is performed during or following an interventional procedure.
-
公开(公告)号:US20230331781A1
公开(公告)日:2023-10-19
申请号:US18323210
申请日:2023-05-24
Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. , Hadasit Medical Research Services and Development Ltd.
Inventor: Rachel BAR-SHAVIT , Chaim GILON , Amnon HOFFMAN , Beatrice UZIELY
Abstract: The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provided as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer such as cancer expressing PAR proteins such as cancer expressing ErbB protein and triple negative cancer. and inhibiting interactions between PARs and protein comprising PH-domain.
-
36.
公开(公告)号:US20230290513A1
公开(公告)日:2023-09-14
申请号:US18017196
申请日:2020-07-22
Applicant: UNIVERSITA’ DEGLI STUDI DI PADOVA , UNIVERSITA’ DEGLI STUDI DI TORINO , AZIENDO OSPEDALIERA UNIVERSITARIA MODENA , NEMO LAB SRL , THE MEDICAL RESEARCH, INFRASTRUCTURE AND HEALTH SERVICES FUND OF THE TEL-AVIV MEDICAL CENTER , ISTITUTI CLINICI SCIENTIFICl MAUGERI , HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventor: Barbara DI CAMILLO , Alessandro ZANDONA' , Sebastian DABERDAKU , Erica TAVAZZI , Adriano CHIO' , Rosario VASTA , Andrea CALVO , Cristina MOGLIA , Federico CASALE , Fabrizio D'OVIDIO , Jessica MANDRIOLI , Christian LUNETTA , Vivian DRORY , Gabriele MORA , Marc GOTKINE
Abstract: A method is described for determining a disease progression and survival prognosis, at a succession of prediction times, for patients suffering from amyotrophic lateral sclerosis (ALS). The method comprises a step of defining a set of variables associated with the onset and progression of amyotrophic lateral sclerosis, comprising a first group of variables associated with the onset of amyotrophic lateral sclerosis (comprising at least the variables “patient sex”, “disease onset age”, “disease onset site”), a second group of dynamic time variables (comprising at least the variable “time elapsed since disease onset”), a third group of dynamic functional variables (comprising at least one of the variables breathing, swallowing, communicating, walking/self-care or at least one variable of a functional progression and/or severity scale of amyotrophic lateral sclerosis), and further at least one variable associated with survival. The method further provides for encoding by means of a Dynamic Bayesian Network, using at least one trained algorithm, a plurality of probabilistic conditional dependence relationships, in which each relationship is a probabilistic conditional dependence relationship between two of the aforesaid variables. The aforesaid prediction times are defined so that each prediction time belongs to a respective time interval in which the conditional dependence relationships between the variables are stationary. The method further involves describing the Dynamic Bayesian Network, using at least one trained algorithm, by means of a corresponding graph, comprising said variables as nodes and comprising topological connections oriented between nodes corresponding to variables among which a probabilistic conditional dependence is identified. In the graph, given a node, the connections entering it show a conditional probability of the value assumed by the variable associated with such node, in a given prediction time, depending on the values assumed, in a prior prediction time, from the variables associated with the nodes from which such connections originate. The method further comprises the steps of entering, for each of the defined variables, data acquired at a given acquisition time relating to the situation of a specific patient; and calculating, by electronic processing and/or calculating means, on the basis of the Dynamic Bayesian Network and the graph, and starting from the aforesaid acquired data, the values of each of the defined variables, at one or more prediction times following the acquisition time. Finally, the method involves obtaining, in a given prediction time, disease progression prognosis results on the basis of the values of one or more of the variables of the third group calculated in such prediction time; and the survival prognosis results on the basis of the value of at least one variable associated with survival, calculated at such prediction time.
-
37.
公开(公告)号:US20230157896A1
公开(公告)日:2023-05-25
申请号:US17801661
申请日:2021-03-11
Applicant: National University of Singapore , Hadasit Medical Research Services And Development Ltd , Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
Inventor: Menachem Gross , Shlomo Magdassi , Yin Chiang Boey , Ngeow Khing Chia
CPC classification number: A61F11/20 , A61B1/227 , A61F2/18 , A61F2002/183
Abstract: The present invention relates to a device for repair of a region within an ear via a natural orifice, the device comprising a body. The body comprises a first port for visibly identifying the region to be sealed, the region being inside the ear; and a second port through which a seal can be introduced into the ear through the device. The region comprises a perforation of a tympanic membrane of the ear and the device is a speculum. The present invention also relates to method for repairing a perforation in a tympanic membrane using the same device.
-
公开(公告)号:US20230065065A1
公开(公告)日:2023-03-02
申请号:US17975214
申请日:2022-10-27
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , RAMOT AT TEL-AVIV UNIVERSITY LTD.
Inventor: Or KAKHLON , Miguel Enrique WEIL , Leonardo Javier SOLMESKY
IPC: C07D409/12 , A61P25/28 , C07D487/08
Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.
-
公开(公告)号:US20220370558A1
公开(公告)日:2022-11-24
申请号:US17622225
申请日:2020-06-23
Inventor: Michal Lotem , Emma Hajaj , Galit Eisenberg
IPC: A61K38/17 , A61K39/395 , A61K35/17 , A61P35/00
Abstract: The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.
-
公开(公告)号:US20220339101A1
公开(公告)日:2022-10-27
申请号:US17852803
申请日:2022-06-29
Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. , YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Inventor: Ruth GABIZON , Haim Ovadia , Oded Abramsky , Shlomo Magdassi , Liraz Larush
IPC: A61K9/107 , A23L33/115 , A61K47/14 , A61K47/24 , A61K47/26 , A61K47/44 , A61K31/202 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/22
Abstract: The present invention relates to the use of pomegranate oil and fractions thereof for preventing and treating neurodegenarative diseases. Particularly, the present invention relates to emulsions of the pomegranate oil or fractions thereof for the prevention and treatment of brain diseases, including Creutzfeldt-Jacob disease (CJD) and multiple sclerosis (MS).
-
-
-
-
-
-
-
-
-